Main Issues
Reasons why we do what we do and that lead us to our mission:
Improve early breast cancer diagnosis
HIGH INCIDENCE OF BREAST CANCER
TECHNOLOGICAL LIMITATIONS
Main Issues
Reasons why we do what we do and that lead us to our mission:
Improve early breast cancer diagnosis
HIGH INCIDENCE OF BREAST CANCER
TECHNOLOGICAL LIMITATIONS
Competitive Advantages
Metabolic information
Portable, no infrastructure required
High specificity
No specialized operator and autonomous
No ionizing radiation.
Suitable for all patients
Our team and partners make all this possible!
Competitive Advantages
Metabolic information
Portable, no infrastructure required
High specificity
No specialized operator and autonomous
No ionizing radiation
Suitable for all patients
THANKS TO
Our team and partners make all this possible!
Managing Team
Pamela Pardini, PhD / CEO
Nicolás Carbone, PhD / CTO
Board of Directors
Alberto Rodriguez Navarro, MD
Oren Gershtein
Main Advisor
Pamela Munster, MD
UCSF
Board of Directors
Alberto Rodriguez Navarro, MD
Oren Gershtein
Pamela Pardini, PhD / CEO
Main Advisor
Pamela Munster, MD
UCSF
Scientific Team
|
|
|
|
|
|
|
|
Scientific Team
Facts & Goals
-
2005
Foundation of Biomedical Optics Group
-
2011
Optical mammography device idea
-
2017
Prendete award
-
2018
IB50k Award
-
2020
Birth of Bionirs
-
2020
CITES investment
-
2021
First prototype
-
2021
IP - national phases
-
2022
First clinical trials
-
2022
2nd prototype
Facts & Goals
2005
Foundation of Biomedical Optics Group
2011
Optical mammography device idea
2017
Prendete award
2018
IB50k Award
2020
Birth of Bionirs
2020
CITES investment
2021
First prototype
2021
IP - national phases
2022
First clinical trials
2022
2nd prototype
Become a partner!
UNICEN Campus Universitario – Tandil, Buenos Aires, Argentina contacto@bionirs.com
Follow us!
bionirs